134 related articles for article (PubMed ID: 17102565)
21. Rapid onset psychosis after reduction of the risperidone dose.
Molina JD; Solé S; Pablo Sd; López-Muñoz F; Santana G; Alamo C
Pharmacopsychiatry; 2008 Jul; 41(4):160-3. PubMed ID: 18651347
[No Abstract] [Full Text] [Related]
22. Significant elevations of prolactin levels in patients who shifted from conventional depot antipsychotics to long-acting risperidone.
Lai YC; Chiou CC; Chen CH; Huang MC
J Clin Psychopharmacol; 2007 Oct; 27(5):523-4. PubMed ID: 17873693
[No Abstract] [Full Text] [Related]
23. Early onset of treatment effects with oral risperidone.
Raedler TJ; Schreiner A; Naber D; Wiedemann K
BMC Psychiatry; 2007 Jan; 7():4. PubMed ID: 17239237
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and safety of combination therapy with lithium and risperidone.
Demling JH; Huang ML; Remmerie B; Mannaert E; Sperling W
Pharmacopsychiatry; 2006 Nov; 39(6):230-1. PubMed ID: 17124646
[No Abstract] [Full Text] [Related]
25. Sexual disinhibition in schizophrenia possibly induced by risperidone and quetiapine.
Lam MH; Fong SY; Wing YK
Psychiatry Clin Neurosci; 2007 Jun; 61(3):333. PubMed ID: 17472606
[No Abstract] [Full Text] [Related]
26. Paliperidone-induced dystonic Dysphagia.
Mendhekar DN; Agarwal A
J Neuropsychiatry Clin Neurosci; 2010; 22(4):451-v.e37-451.e37. PubMed ID: 21037154
[No Abstract] [Full Text] [Related]
27. Hypomania induced by atypical antipsychotics among schizophrenic patients: report of three cases.
Baldaçara L; de Castro Ferrari MC; Monteiro BF; Uchida RR; Sanches M
Pharmacopsychiatry; 2007 Jul; 40(4):169-70. PubMed ID: 17694481
[TBL] [Abstract][Full Text] [Related]
28. Quetiapine-related dysphagia.
Armstrong D; Ahuja N; Lloyd AJ
Psychosomatics; 2008; 49(5):450-2. PubMed ID: 18794516
[No Abstract] [Full Text] [Related]
29. Priapism resulting from sertralinerisperidone combination in a 30-year-old Nigerian man with schizophrenia.
Salawu FK; Mustapha H; Danburam A
Ann Afr Med; 2010; 9(3):195. PubMed ID: 20710115
[No Abstract] [Full Text] [Related]
30. The disparity of pharmacokinetics and prolactin study for risperidone long-acting injection.
Peng PW; Huang MC; Tsai CJ; Pan CH; Chen CC; Chiu CC
J Clin Psychopharmacol; 2008 Dec; 28(6):726-7; author reply 727-8. PubMed ID: 19011459
[No Abstract] [Full Text] [Related]
31. Rapidly disintegrating risperidone in subjects with schizophrenia or schizoaffective disorder: a summary of ten phase I clinical trials assessing taste, tablet disintegration time, bioequivalence, and tolerability.
Thyssen A; Remmerie B; D'Hoore P; Kushner S; Mannaert E
Clin Ther; 2007 Feb; 29(2):290-304. PubMed ID: 17472821
[TBL] [Abstract][Full Text] [Related]
32. New-onset diabetic ketoacidosis in a schizophrenic patient with multiple autoimmune disease during treatment with risperidone.
Sato Y; Yasui-Furukori N; Kaneko S; Moriyama T
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):577-8. PubMed ID: 17919798
[No Abstract] [Full Text] [Related]
33. Pharmacokinetics study for hyperprolactinemia among schizophrenics switched from risperidone to risperidone long-acting injection.
Bai YM; Chen TT; Lin WK; Chang WH; Wu B; Hung CH; Chou P; Chen JY
J Clin Psychopharmacol; 2007 Jun; 27(3):306-8. PubMed ID: 17502783
[No Abstract] [Full Text] [Related]
34. Neuroleptic-associated dysphagia confirmed by esophageal manometry.
Moss HB; Green A
Am J Psychiatry; 1982 Apr; 139(4):515-6. PubMed ID: 6121491
[No Abstract] [Full Text] [Related]
35. [Improvement of dysphagia with motor disorders after stopping neuroleptic treatment].
Levy P; Feydy P
Gastroenterol Clin Biol; 1997; 21(11):894-5. PubMed ID: 9587544
[No Abstract] [Full Text] [Related]
36. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: a randomized double-blind pilot trial.
Byerly MJ; Nakonezny PA; Rush AJ
Psychiatry Res; 2008 May; 159(1-2):115-20. PubMed ID: 18295343
[TBL] [Abstract][Full Text] [Related]
37. Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.
Keith S
Expert Rev Neurother; 2009 Jan; 9(1):9-31. PubMed ID: 19102665
[TBL] [Abstract][Full Text] [Related]
38. Blood pressure, heart rate, and anxiety in schizophrenia.
Townsend MH; Baier MB; Becker JE; Ritchie MA
Psychiatry Res; 2007 May; 151(1-2):155-7. PubMed ID: 17376539
[TBL] [Abstract][Full Text] [Related]
39. Randomized clinical comparison of perospirone and risperidone in patients with schizophrenia: Kansai Psychiatric Multicenter Study.
Okugawa G; Kato M; Wakeno M; Koh J; Morikawa M; Matsumoto N; Shinosaki K; Yoneda H; Kishimoto T; Kinoshita T
Psychiatry Clin Neurosci; 2009 Jun; 63(3):322-8. PubMed ID: 19566763
[TBL] [Abstract][Full Text] [Related]
40. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
